Real-world Effectiveness of the Adjuvanted Recombinant Zoster Vaccine in ≥50-year-old Adults With Autoimmune Diseases.

ABSTRACT:

Background

Real-world data on the vaccine effectiveness (VE) of the adjuvanted recombinant zoster vaccine (RZV) to prevent herpes zoster (HZ) among individuals with autoimmune diseases (AIDs) are limited. To address this knowledge gap, we aimed to evaluate the VE of 2 RZV doses against HZ in ≥50-year-old adults with selected AIDs (rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus, multiple sclerosis (MS), psoriasis (PsO), and psoriatic arthritis).

Methods

We conducted a retrospective matched cohort study using Optum's deidentified Clinformatics® Data Mart Database datasets from January 2018 to December 2021. Patients were matched by AID condition, age, and medication category, then 1:3 by propensity scores that accounted for the likelihood of rec

SUBMITTER: Constenla D 

PROVIDER: S-EPMC12718021 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature